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1. Introduction 
Schizophrenia is possibly the most notorious of the mental illnesses and the lack of popular 
understanding of it, with consequent understandable discomfort upon receipt of the 
diagnosis, persists to the present day. The evolution of terms to describe what is usually 
understood by health workers in the UK as learning disability is a useful illustration of how 
mental illness generally has come to be understood. :- 
 
English Mental IQ under 20 IQ 20-30 IQ 50-70 
Deficiency Acts 
1913-1927 
Idiocy Imbecility Feeble-mindedndess 
 
Mental Heath Act, IQ 0-50 IQ 50-70 
England & Wales 
1959 
Severe subnormality subnormality 
 
Mental Heath Act, IQ 0-50 IQ 50-70 
England & Wales 
1983 
Severe mental impairment  Mental impairment 
 (in both instances, previously popularly known as ‘mental handicap’). 
     
ICD-10 IQ rating under 20 IQ 20 - 34 IQ 35-49 IQ 50-69 
1992 Profound learning 
disability (LD) 
Severe LD Moderate LD Mild LD 
 
Fig. 1. Progression of statutory understanding of intellectual impairment in the UK. 
....Indeed, any condition which affects neurological or intellectual functioning has 
progressed through an analogous course of understanding. Epilepsy, which is now known 
to be an abnormality in cerebral neural transmission, was thought of in earlier times to be 
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perhaps a visitation from God or indicative of shamanic ability. Such lurid explanations 
are now no longer felt to be appropriate, as more has become known about the underlying 
pathology. The progression of terms used in the understanding of learning disability is an 
example of similar development. The progression of understanding of schizophrenia in 
the 20th century has been aided by inductive appreciation of the pharmacology of the 
illness. This idea will be further considered later on here. Although the progression of 
knowledge is necessarily contemporaneous on all fronts, public perception of it is 
undoubtedly affected by the social milieu. Thus, in the progression of understanding of 
schizophrenia, the first step is that the condition was a result of external forces, such as a 
result of celestial actions, or of God (in monotheistic cultures). Next, there was an 
understanding of the importance of direct social factors, such as family and immediate 
social environment. A reflection upon the psychological effects of these led to the final 
step in this progression: the role of an affected person’s biology. Physiological and 
ultimately, neurophysiological and biochemical alterations in the disease process are 
deliberated upon at this final stage of understanding. 
Geekie and Read, in 2009, provide an elegant expression of how a narrative framework 
allows a protagonist – such as the affected individual, or society – to make sense of their 
experiences. Thus, in the attempt to understand mental illness, alternative narrative 
frameworks include: 
- madness as a result of the whim of the deities (a view prevalent in ancient Greece, for 
example) 
- the same disturbances being understood as the result of one’s life experiences or 
circumstances 
- “ “ as a result of faulty brain chemistry. 
“Within the storytelling framework, we might say that these are all different ways of 
‘storying’ the experience of madness.” (1) 
...Where “storying” can be understood as placing within a narrative framework in order to make the 
phenomenon intelligible.  
There are, of course, multiple possible narrative frameworks. If one is considering the 
evolution of understanding of schizophrenia, then theological, sociological and 
biochemical explanatory modes can all be understood as different types of narrative 
framework. Each attempts to provide a comprehensive explanation for the disorder. 
Multiple types of explanation exist for many reasons: cultural factors, which include 
geographical and temporal contexts, as well as educational ones, are perhaps the most 
important. In this way, the epistemological foundations of an explanatory mode can be 
easily understood. The existence of several possible types of explanation should lead to 
the understanding that each relevant branch of knowledge has a contribution to make to 
the complete understanding of a subject. Different explanations persist because they are 
useful in their own contexts: therefore, a complete understanding of a subject involves 
attending to all of the potential reasons underlying it. This is summarised in figure 2 on 
the following page. As this figure shows, it is possible to understand that all factors which 
influence a mental illness – for our purposes, schizophrenia – can be appreciated as parts 
of a unified whole, in which every stage will ultimately affect another stage. The 
appreciation of this interconnected nature of phenomena allows a clinician to provide a 
holistic framework for management of the disorder, and is especially useful when dealing 
with the mental illnesses. 
Continued... 
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The cerebral appreciation of any event can be summarised, in extremely simplified terms as: 
 
 
Fig. 2. The interconnected nature of societal, biological and chemical phenomena. 
2. Historical overview of the understanding of schizophrenia 
Moskovitz and Heim remind us that it is one hundred years since Bleuler originally 
proposed the concept of the schizophrenic illnesses, in 1911 (2). In their re-appraisal of 
Eugen Bleuler’s original concept of ‘Dementia Praecox or the Group of Schizophrenias’, it is 
noted that Bleuler’s understanding of this illness was a largely inductive one: he spent a 
great deal of time with his patients at the Burghölzli institute and his understanding of 
schizophrenia emerged from this immersive observation. This is reminiscent of modern 
anthropological fieldwork, and indeed, Bleuler’s study was essentially anthropological. This 
was in marked contrast to the other pioneer of knowledge in schizophrenia, Emil Krapelin. 
Whereas Bleuler’s understanding was ‘bottom up’ and inductive, Krapelin’s was ‘top down’, 
i.e. theory driven and deductive. Both methods of understanding can produce valuable 
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conclusions. The appropriate task to facilitate a complete understanding is to attempt to 
bring the multiple sets of theories together in a unified and logical whole. Reference to 
figure 2, on the previous page, can help with this. 
Moskovitz and Heim (2) inform us that the term ‘schizophrenia’ was effectively coined by 
Bleuler in 1911. It is perfectly possible that some of the rather vivid explanations noted 
above were similarly previously used to render a phenomenon resembling schizophrenia 
intelligible, by placing it within a clear narrative framework.  
Romme et al (3) discuss the case of perhaps one of the most famous voice-hearers in history, 
St. Jeanne D’Arc [Joan of Arc]. ‘Voice-hearing’ here refers to a particular subtype of the 
psychiatric symptom of auditory hallucination. Auditory hallucination – i.e. hearing audible 
sounds (including intelligible voices either speaking to or about the affected person) in clear 
consciousness when there is no physical cause for them – may be an important symptom of 
schizophrenia. In schizophrenic illness, there are often associated ideas which make sense of 
this symptom; these ideas can solidify into unshakeable associated, consequent delusions. 
Hence, delusions are performing the storying function (1), rendering the psychotic 
phenomena intelligible to the person who is experiencing them.  
Romme et al discuss how auditory hallucinations, rather than being dismissed out of hand 
as an indication of psychosis and thus disregarded, can be actively worked with. This 
validation of the affected person’s symptoms is an important element in that person’s 
eventual recovery. There are several alternative explanations for the phenomenon of voice-
hearing. A wry aphorism about this is that if you talk to God, you are religious, whereas if 
God talks to you, you’re schizophrenic. As a clinician, I have always noticed that a psychotic 
person’s delusions are reflective of the current temporal context. The cover of the book by 
Professor Romme and colleagues about voice-hearing and recovery depicts Jeanne D’Arc in 
battle. She was a French peasant girl who claimed to hear the voice of God calling upon her 
to free her nation from English domination. This occurred towards the end of the Hundred 
Years War (1337-1453). Jeanne D’Arc led her compatriots to many important victories as a 
result of this ‘divine guidance’. After her capture, at the age of nineteen in 1431, she was 
tried and burned at the stake as a witch. Subsequent regal, then ecclesiastical intervention 
saw her first declared as a martyr and much later, beatified. In the early twentieth century, 
she was canonized and as St. Jeanne D’Arc, is one of the five patron saints of France (3). This 
reflects the importance of the cultural context of auditory hallucinations and their 
interpretation. In fifteenth century Catholic France, ‘hearing the voice of God’ could 
reasonably have been understood as a sign of divine communication. Therefore, the ‘divine 
direction’ of Joan of Arc to free her nation from the English in the 1420s would have been 
unsurprising. In late twentieth and twenty-first centuries in rich industrialised countries, a 
similar phenomenon would be understood as a sign of psychosis which represents an 
indication for therapy, most usually pharmacological.  
It is worthwhile to briefly reflect upon the history of the treatment of people with mental 
illness. The profound lack of understanding of, and inability to explain, mental illness led to 
the majority of people affected by it to be excluded from society: indeed, the archaic term for 
a psychiatrist is alienist, which implies involvement with those outside the usual boundaries 
of society. A few voice-hearers, such as Jeanne D’Arc, have played important historical 
roles. The vast majority of others, however, together with their affected fellows, were 
excluded from society. From the seventeenth century onwards, this was often in large 
lunatic asylums. Medical involvement in such asylums was confined to treating the physical 
maladies of the residents. It was not until the mid to late eighteenth century that figures 
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such as Pinel in Paris and Chiarugi in Tuscany began to advocate the humane treatment of 
asylum inmates. Pinel, together with his overseer Pussin at the Bicêtre hospital in Paris 
introduced compassionate reforms in the management of the patients there (4). Their later 
contemporary Chiarugi, in Tuscany in 1789, asserted that: 
“...it is a supreme moral duty and medical obligation to respect the mental patient as a 
person” (4). 
The foundations of the Italian therapeutic movement known as Democratic Psychiatry can be 
seen here. This sequence of events represented an enormous progression in the care of the 
mentally ill. Pinel later (in 1801) emphatically advocated for the inclusion of mental 
disorders as a branch of medicine. As a result, he is regarded as the originator of psychiatry 
as a medical discipline. Thus, we can say – in light of the earlier remarks here- that Pinel 
brought psychiatry into the narrative framework of medicine.  
While the introduction of humane treatment of the mentally ill represented a significant 
advance on previous approaches, the discovery of effective psychotropic medications was 
really what ‘unlocked the doors of the asylums’. It was not until the discovery of lithium 
salts as an effective treatment of mania (by Cade in 1949) and the synthesis and subsequent 
use of chlorpromazine as a major tranquiliser (by Delay and Deniker in 1952) that people 
who had previously been destined to spend the rest of their lives in asylums could 
reasonably expect to return to society. Since then, the understanding and development of 
drug treatments for mental illness has grown apace. The pharmacological appreciation of 
the nature of schizophrenia began by studying the known chemical effects of the major 
tranquilisers such as chlorpromazine. Recognition that this drug blocked dopamine 
receptors - potentially leading to symptoms of iatrogenic Parkinsonism - is what preceded 
the subsequent explosion of neurochemical understanding of schizophrenia. In this way, by 
effectively working backwards from the known biochemical effects of a medication, the 
neuropathology of particular illnesses has come to be appreciated. In other words, inductive 
reasoning from known psychotropic drug actions led to the understanding of the bases of 
pathology of these illnesses. Of course, this understanding has continued to grow and some 
of the consequent latest developments in the neurophysiological field will be considered 
later on here. 
3. Current pharmacological and neurophysiological knowledge about 
schizophrenia 
As indicated above, the first instances of this were arrived at by inductive reasoning about 
the mechanisms of action of the earliest widely-available psychotropic drugs. In the process 
of obtaining supplementary information about this knowledge, areas requiring further 
investigation have, of course, been opened up. Some of these were to further understand the 
pharmacological mechanisms and some of this work has necessarily explored the 
underlying neuropathology of schizophrenia. In the process of doing so, further therapeutic 
avenues became apparent. Miyamoto et al (5) wrote a comprehensive review of 
pharmacological treatments for schizophrenia in 2005. Important work had already been 
carried out on the detailed neurophysiology and pathology of the disease: in my opinion, 
the most significant findings were about the importance of sensory gating (6, 7) and of the 
roles of excitotoxicity (8) and apoptosis (9) in the presentation of, and progression of this 
disease. Site-specific dopamine receptor activity can be influenced either by (e.g.) 
interneuronal sensory gating or by a simple dose-response effect: in the latter case, a high 
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receptor density implies that low doses of the particular agent will affect that receptor. In 
contrast, a low receptor density requires a higher dose of binding agent. For example, the 
second-generation antipsychotic agents sulpride and amisulpiride have differing biological 
profiles at different doses. These drugs bind to dopamine D2 receptors in the temporal lobe 
cortex at low doses, conferring their excellent antipsychotic activity. At higher doses, these 
agents bind to D2 receptors in the corpus striatum, causing difficult extra-pyramidal side 
effects -again, including iatrogenic Parkinsonian symptoms (5). Therefore, this implies that 
D2 receptors are at a high density in the temporal cortex, but at a lower density in the 
striatum, which explains the dose-response effect. At other sites, such as area CA3 of the 
hippocampus, interneuronal sensory gating is the phenomenon which determines post-
synaptic D2 activity (10).  
Miyamoto et al (5) remind us that for any antipsychotic drug to be clinically effective, it must 
display occupancy of cerebral dopamine D2 receptors. As we have already seen, the 
particular site of the involved D2 receptor is important. To reiterate, this can be partly 
determined physiologically (e.g. pre-synaptically), or physically, by the ratio of available 
drug to available receptor site. 
Dopamine receptor blockade was the main mode of action of the first-generation 
antipsychotic drugs: however, the therapeutic window available for this is extremely 
narrow. The optimal level of cerebral D2 receptor occupancy classically lies only between 
65% to 70%. Below this, there is often no clinical response – although there are a few affected 
people who will show a therapeutic response to very low doses of antipsychotic drug. 
Above this level of receptor occupancy, symptoms of iatrogenic Parkinsonism, such as 
tardive dyskinesia, become a real problem. This is further complicated by the fact that 
chronic treatment with the first-generation (‘typical’) antipsychotic drugs causes a 
homeostatic increase of D2 receptors (5). Of course, chronic treatment is the most usual 
clinical scenario. Ken Steele, a now deceased, well-known advocate of service users’ rights 
in the United States, summarised this succinctly. – 
“...Just as a diabetic needs to take insulin to control diabetes, a schizophrenic must remain 
on medication- each and every day. It’s a question of maintenance. ...Schizophrenia is a 
disease that can be controlled, but not yet cured. “ (11, original emphasis) 
Steele correctly emphasised the chronic nature of pharmacological treatment for 
schizophrenia. Although he was writing in 2001, the position is unchanged today, some 10 
years later: schizophrenia remains “...a disease that can be controlled, but not yet cured”. 
Empirical experience with the first generation of antipsychotic drugs showed that the D2 
receptor model clearly could not explain the whole pathological picture of schizophrenia. 
Work was therefore understandably directed towards trying to find out more about this, 
because it became apparent that schizophrenia is not simply a process of excessive dopaminergic 
activity centred on the cerebral D2 receptors. In order to further elucidate the neuropathology of 
schizophrenia, one important branch of work has investigated the role of sensory gating in 
schizophrenia (6, 7, 10, 12). Sensory gating is the process where the conscious mind devotes 
the majority of its attention to the task which it is directly presented with. Other sensory 
stimuli are deemed irrelevant while the task in hand is focussed on. A formal definition is 
given by Potter et al (12): ‘‘. . . Sensory gating refers to the pre-attentional habituation of 
responses to repeated exposure to the same sensory stimulus.” [my emphasis]. 
A further explanation of this is given by Conway in 2009 (10):  
“...Efficient sensory gating allows a person to ’screen out’, or ignore background stimuli, 
such as the noise of a ventilation motor, or traffic outside a window. If the person is unable 
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to do this, as in acute schizophrenia, the now intrusive stimulus may acquire a delusional 
significance. This is explicable by the pathological cerebral functioning which occurs in 
schizophrenia: delusions may represent a conscious attempt by the person to comprehend 
the contemporaneous neurophysiological events in his/her brain. Correctly functioning 
sensory gating stops the possible misinterpretation of cerebral events.” 
Javanbakht (7) notes that there is a “...fronto-limbic imbalance...” which he proposes as one 
of the causes of disrupted sensory gating. I would propose that excitotoxicity (8) is perhaps 
the cause of this imbalance: excitotoxicity represents the consequence of unremitting 
neuronal stimulation. One result of this is that the content of affected neurones is exhausted 
and the resultant cellular debris is catabolised by astrocytes. These latter cells are acting, in 
effect, as cerebral macrophages, clearing the non-functional cellular material produced as a 
result of apoptosis (9). Repeated exacerbations of schizophrenia result in repeated instances 
of apoptosis, ultimately leading to the cortical (frontal) atrophy typical of chronic 
schizophrenia. Therefore, a functional fronto-limbic imbalance could be caused by 
excitotoxic, apoptotic tissue loss in the (pre) frontal cortex. The especially aggressive 
pathological process which underlies schizophrenia is exemplified by the fact that negative 
symptoms – which are a possible consequence of cerebral hypofunction caused by actual 
apoptotic neuronal loss –can be seen in a first attack of schizophrenia (10).  
Unremitting cortico-limbic stimulation can be prevented by correctly functioning sensory 
gating (6, 7, 10, 12, 13). Here, nicotinic activation, especially of hippocampal area CA3 (10, 13) 
will prevent this unremitting stimulation, and its apoptotic consequence (9). The operative 
nicotinic receptor - the α7 receptor in area CA3 of the hippocampus - (7, 10, 13) desensitises 
very quickly. Short bursts of nicotinic enhancement, such as that provided by cigarette 
smoking (10, 13) – or theoretically by nicotine chewing-gum – would, importantly, allow a 
transient normalisation of dysfunctional sensory gating. Therefore, the notoriously heavy 
cigarette-smoking rate of people with schizophrenia, an attempt at self-medication, (10, 13, 
14, 15, 16, 17) might be preventable and thus, important health benefits could be afforded to 
this vulnerable patient group if the role of nicotinic transmission is remembered (10).  
The search for more efficient antipsychotic medication was stimulated, in part, by the 
experience of the limited efficacy of antipsychotic drugs which had existed hitherto. Certainly 
the currently available antipsychotic agents represent a great advance on their earlier 
predecessors, although they are not without difficult side-effects of their own. This simple fact 
tells us that our understanding of schizophrenia remains incomplete. It was noted above how 
a relatively simple entity such as dose-response can give an indication about comparative site-
specific receptor density. Such working hypotheses can now, fortunately, be confirmed or 
refuted with the help of powerful neuroimaging techniques such as positron emission 
tomography (PET scanning), single-photon emission computed tomography (SPECT 
scanning), or functional magnetic resonance (fMRI) scanning. However, perhaps the most 
important factor with regard to pharmacological treatments for schizophrenia is to emphasise 
the necessity for lifelong continuation of medication such that the inherent pathology is not allowed 
to progress. Attention is again drawn to Ken Steele’s quote (11): schizophrenia is exactly 
analogous to diabetes, but the schizophrenic illness process affects the brain.  
4. Psychological approaches to the management of schizophrenic illness 
Of course, pharmacological treatments are not the only option in schizophrenia. 
Remembering the importance of holistic treatment – for any illness – one should consider 
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non-medication based adjunctive managements as part of a treatment package. Following 
on from the statement immediately above, any illness which affects the brain will also 
consequently affect the mind, thus allowing the possibility of psychological treatments. 
(This rubric also includes the social manipulations employed therapeutically in this illness.) 
These have proved to be particularly successful in schizophrenia when employed as part 
of a treatment programme including appropriate pharmacological and social adjustments. 
Not only does psychological treatment provide a useful adjunct to pharmacological 
treatment, it has been shown to lower the maintenance medication requirement in this 
illness (18). In a thoughtful 2004 paper about the efficacy of cognitive behaviour therapy 
(CBT) for psychotic illness, Tarrier and Wykes performed a meta- analysis of 20 
randomised controlled trails of CBT compared to treatment as usual. They found that 14 
of these trails had at least “...a small [positive] effect size, and 3 a large [positive] effect 
size” (18). These authors drew the cautious conclusion that CBT for psychosis was thus 
able to reduce positive symptoms in schizophrenia (and therefore the need for 
antipsychotic medication). 
A large contributor to this was the effect of listening to the affected person’s symptoms. The 
value of listening to symptoms really cannot be overemphasised, principally because of two 
important issues:  
• the validation of an affected person’s experience  and 
•  assessment of the current progression of pathology. 
Barker et al (19) noted that in their study, both the affected people themselves and their 
immediate social contacts were “not heard by professionals”, and their beliefs and opinions 
about the illness process were discounted. Nine years later, Owens et al (20) identified “...an 
existing dearth of evidence on service users’ experiences of mental health services.” This 
implies that subjective experience of the affected person in mental illness continues to be 
ignored. The importance of listening to symptoms is that they can clearly tell the observer 
about the likely coincident pathology. The table on the next page is produced from a first-
hand account of the progression of schizophrenia (21), which I have correlated with the 
likely coincident neuropathology.  
Thus, one of the most useful features of the psychological approaches to the management of 
schizophrenia is validation of the affected person’s experience. As one can see from the following 
table, by listening to the affected person, a clinician obtains a very clear expression of the 
likely current pathology. The first-hand effect of not listening to an affected person’s 
symptoms is neatly summarised in the following quote, from a mental health academic who 
had spent twelve months being detained in hospital under the Mental Health Act, with 
schizophrenia. - 
“...My strange religious beliefs were perhaps quite rightly classified as delusional and 
discounted...but this left me with the impression that my experiences...were also being discounted...” 
(24, my emphasis) 
The point made above and in Figure 3, about the importance of listening to the content of 
hallucinatory voices perhaps reminds us of perhaps how short-sighted this person’s 
clinicians were. As another example of the importance of listening, the testimonial data 
collected by Barker et al is sobering for a therapeutic readership. – 
“...They all said the same things: you’re hallucinating, they said. I thought: what’s caused 
this? So they said the damaged area of the head, this bit round here [no indication of area 
given in transcript], that’s all I was told, really.” 
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Reported subjective experience: verbatim 
 quotes from Snyder (21). 
Comment, including when relevant, possible 
operative neuropathology. 
“I developed schizophrenia gradually over 
a period of nine years, with the most 
severe symptoms appearing when I was 
twenty-eight years old.” 
This puts his probable age of onset at nineteen 
years old. Late adolescence is the typical age of 
onset for the schizophrenic illnesses, which 
require sufficient maturity in the affected neural 
pathways before the pathology can express 
itself.  
“I cannot think of anything physical or 
psychological that could have triggered a 
change in my mental state. I had 
wonderful, supportive parents, relatives 
and friends, and I had a wonderful 
childhood.” 
The onset of a psychotic illness is, more often 
than not, triggered by an event which anyone 
would find severely upsetting. The course of the 
illness can be further exacerbated by ongoing 
social or psychological stressors. Mr. Snyder is 
fortunate in that neither of these apply to him, 
suggesting that his illness had a very strong 
neurological basis which, if coupled with the 
above stressors, may well have been much more 
severe. This is an example of the genetic 
heterogeneity of schizophrenic phenotypes. 
“Somewhere between the ages of nineteen 
and twenty-one, I was exposed to the 
mathematical idea of fractals...I thought I 
was going to discover some incredible and 
fabulous mathematical principle that 
would transform the way we view the 
universe...Even though I had no evidence 
to substantiate my self-image, I knew in 
my heart that I was just like Einstein...” 
Here, Mr. Snyder is clearly using a manic defence 
to make sense of his progressive excessive 
mesolimbic dopaminergic discharge. A manic 
defence is where the affected person adopts a 
grandiose explanation for (e.g.) their coincident 
cerebral pathology. Grandiosity can also be a 
feature of transient hyperdopaminergia, as seen 
both in acute schizophrenia and acute mania, or 
in hypomania.  
“At about...twenty-two, I had my first 
significant paranoid episodes...I started to 
think about images from horror movies 
where an insane man breaks into the 
house and kills everyone...later...I hurt 
my leg and...feeling very vulnerable ...the 
nurse might try to infect me with the 
AIDS virus by injecting me with a 
tainted needle...” 
Here, this gentleman is describing what the 
progression of hyperdopaminergic discharge 
feels like. By now he may well have suffered 
some excitotoxic cell damage (8). However, 
because he was fortunate in having numerous 
effective social supports and was well-engaged 
in treatment, his illness was not allowed to 
progress to any significant extent and thus it is 
probable that any excitotoxic cell loss (8) was 
consequently limited. 
 “In my second psychotic episode, I 
experienced for the first time what I 
can confidently say were auditory 
and visual hallucinations...At the 
time, these hallucinations seemed real 
to me, absolutely real...my family 
tried to get me medical help. 
Medications were prescribed, but I 
The aggressive nature of the underlying 
pathology  of Mr. Snyder’s illness is clearly 
demonstrated here. The onset of auditory 
hallucinations may well have been have a 
consequence of disrupted sensory gating (6,10).  
The lack of insight, e.g. the lack of acceptance of 
a psychiatric illness, is common for people 
affected by severe psychoses. To paraphrase 
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refused to take them. I didn’t believe 
anything was wrong with me... – 
those pills were for crazy people!” 
Nelson (22), hallucinatory voices and their 
consequent belief systems are as real and 
rational to the affected person as the fact that I 
happen to have two arms and two legs. This is 
what makes schizophrenia such a problematic 
illness to treat: like all the mental illnesses, it 
profoundly alters one’s experience of reality. As 
such, the protagonists’ reality at the time has to 
be actively worked with in order for this person 
to move forward productively. 
“After several months I finally 
decided to take the medication 
(Geodon) [=ziprasidone]...I 
developed a severe case of 
depression...I wanted to die rather 
than continue to experience this 
feeling...At the end of my second year 
taking Geodon, I began to experience 
severe akathisia. This unusual type of 
anxiety is the worst emotional 
experience I have ever experienced in 
my entire life...” 
Depression is a very common part of the 
pathological progression of schizophrenia: it’s 
appearance is so common that it may well be an 
intrinsic consequence of the underlying 
pathology- possibly due to excitotoxicity (8) 
caused by apoptosis (9). Akathisia is a type of 
physical restlessness which is uncontrollable: the 
affected person has, scatalogically, extremely 
severe ‘ants in their pants’.  
“My doctor switched my medication 
to Zyprexa [=olanzapine], and the 
akathisia gradually diminished...I 
now believe that I have fully 
recovered from schizophrenia, and I 
realise that my recovery is owed 
entirely to medication...I did not 
pursue any type of psychoanalysis. I 
simply took the medication...” 
The idiosyncratic nature of a person’s response 
to treatment is well-demonstrated here. Both 
ziprasidone and olanzapine are newer 
antipsychotic medications, which generally have 
far fewer side effects than their older precursors. 
In spite of this, ziprasidone – which reputedly 
has much less tendency to cause weight gain 
than the commonly-used olanzapine – didn’t 
prove suitable for Mr Snyder.  
The fact that he “did not pursue any type of 
psychoanalysis” and still recovered is 
attributable to this gentleman’s excellent social 
supports. This is in marked contrast to other 
first-hand accounts, e.g. Steele (11) and Schiller 
(23): although Mr. Steele was markedly lacking 
in social support, Mr. Snyder was not. This 
again indicates the idiosyncratic nature of 
responses to therapeutic efforts in 
schizophrenia. 
A likely explanation is that there is a continuum 
of severity along the spectrum of schizophrenic 
illness. 
Fig. 3. (above) The probable relationship between symptoms experienced in schizophrenia 
and causative pathology. 
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...and: 
“...they just didn’t want to listen to the patients’ side at all: they would make their diagnoses 
and that was it.”  
(Both verbatim quotes from Barker et al [19]; my addition to first quote.) 
...Again, referring especially to the last comment, the success of the psychological 
managements of schizophrenia, with their essential validation of a person’s symptoms is 
unsurprising. As has been stated earlier here, it can clearly be seen that delusions are an 
attempt by the affected person at storying their experience (1). Another, equally important 
facet of the psychological approaches is the degree of empowerment that they afford the 
affected person (24). Education about the nature of the illness and how an affected person 
can recognise a potential worsening of symptoms and act to prevent an exacerbation is 
extremely important. Employment of psychological techniques of management as part of a 
treatment programme for schizophrenia can render consumption of antipsychotic 
medication an emphatic choice for the affected person rather than passive compliance- the 
latter is unfortunately the usual situation.  
Psychological treatments for schizophrenia include an array of possibilities (18, 22, 25, 26): 
cognitive behavioural therapy [in its many variations] personal therapy, psychotherapy 
[again, with many variations of type] and compliance therapy. All of the psychotherapeutic 
approaches overlap to some degree. A particularly important ingredient of the 
psychological therapies for schizophrenia is the degree of empowerment of the affected 
person: these therapies rely on the agency of the affected person in the maintenance of their 
own health. As has been indicated above, validation, together with empowerment are two 
very important contributors to the improvement in, and maintenance of, ego strength. To 
reiterate an earlier assertion here, the establishment of a robust therapeutic alliance between 
the affected person and the treating team is a significant positive contributor to the eventual 
success of the treatment. The proven success of methods such as cognitive therapy for 
schizophrenia is undoubtedly partly attributable to the affected person’s experiences being 
listened to or validated (19, 20, 23). In cognitive therapy, the affected person him/herself 
becomes the agent of therapeutic change. One facet of cognitive therapy for schizophrenia 
involves the affected person actively challenging a delusional belief. As an example, it is not 
uncommon for a person suffering from acute schizophrenia to believe that they are evil. 
(Hence an acute attack of schizophrenia can include depressive aspects which are 
experienced as delusional beliefs, or as persecutory hallucinatory voices.) In cognitive 
therapy, the protagonist would be advised to challenge this psychotic expression of 
experience by (e.g.) asking the hallucinatory voice to provide evidence for their statement. 
The affected person is taught how to provide evidence to the contrary. Hence, dysfunctional 
thoughts are confronted. This is the general principle of cognitive therapy, wherever it is used.  
To pursue this hypothetical example further: 
Hallucinatory voice: “You’re evil.” 
Affected person: “No I’m not. I do voluntary work at the local charity shop twice a week and they 
really like me there.” 
... and here, the importance of appropriate social manipulations as a therapeutic tool becomes 
evident.  
To combat dysfunctional thoughts, as in this example, the person must have enough ego 
strength to be able to do so. This is the aim of the whole treatment package, but especially 
applies to psychological techniques used in management. The ability to challenge delusional 
beliefs in cognitive therapy or in psychotherapy for psychosis depends on good ego-
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strength in the affected person. Therefore, at first glance, it might seem counter-intuitive to 
employ psychotherapeutic methods in schizophrenia where one of the core pathological 
features is a disruption of the protagonists’ individuality (and thus, by definition, ego-
strength). However, in common with all therapies for all illnesses, the aim of treatment is to 
arrest – or, at the very least, alleviate – the disease process. Psychotherapeutic approaches 
for schizophrenia centre upon maintaining the affected person’s ego-integrity. Psycho-
education is thus an immensely important part of the treatment process. If the affected 
person can understand the need for continued medication and further, if they are able to use 
psychological techniques to combat a resurgence of symptoms should these arise, the 
combination is, again immensely empowering. It is thus unsurprising that the eventual dose 
of maintenance medication can be lowered (18).  
Interested readers are referred to the wealth of excellent practical texts for cognitive therapy 
in schizophrenia, such as Nelson (22). While cognitive therapy has often been successfully 
used to aid compliance with medication, we have seen here that effective therapy of this 
kind with a well-engaged service user is known to reduce the required dose of maintenance 
medication. This is undoubtedly because the affected person can react in a therapeutic 
manner to the resurgence of symptoms. Other approaches to the presence of hallucinatory 
voices in schizophrenia include using distraction techniques: some affected people find that 
listening to music on a personal stereo blocks or drowns out their hallucinatory voices.  
As proponents of psychotherapy for the psychoses readily agree, psychotherapy is not a 
suitable treatment option for everyone affected by schizophrenia. Again, this is perfectly 
intelligible: while there are treatment approaches which are generally applicable – such as 
the employment of a drug which has some dopamine D2 antagonism as an antipsychotic 
measure - each treatment regime must ideally be individually tailored as far as possible. 
One is referred again to figure 2, to be reminded of the holistic picture in treatment of 
mental illness. The importance of the holistic picture is emphasised in a review edited by 
Gleeson, Killackey and Krstev (27): within this review, the assertion is that a therapeutic 
alliance between proponents of the biochemical and psychodynamic models of 
schizophrenia is long overdue. Several essays within the review echo this sentiment.  
5. Social manipulations in the treatment of schizophrenia 
Social and psychological manipulations for illness overlap to a slight degree, most obviously 
in their therapeutic effects. The theoretical example of combating dysfunctional beliefs in the 
cognitive treatment of schizophrenia above indicates how important social conditions are. 
Remembering (from figure 2) that social events produce physiological changes, it is essential 
to consider a person’s social situation when attempting to optimise their functional capacity. 
Therefore, the affected person must be in a stable and appropriate living situation: the high 
frequency of serious mental illness in the homeless and vulnerably housed population is 
testament to the importance of the ‘home’ situation. While some people with schizophrenia 
are able, with regular medication and regular clinical review, to maintain paid employment, 
not everyone is this position is. The usefulness of the attention of a social worker, or 
similarly qualified professional who has expertise in negotiating fields such as finance, 
housing and employment, is evident. Active feedback between all specialist practitioners 
about an affected person is essential: this is the model of the old Community Mental Health 
Team (CMHT) in the UK. The usefulness of this particular model is that a single group of 
practitioners gets to know the ill person well, and is aware of factors which may alleviate, or 
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aggravate their illness. The current (2011) fragmentation of care in the UK therefore can be 
potentially unhelpful for the affected person. It is well-recognised that the CMHT can 
become a surrogate family for the person with a chronic illness such as schizophrenia. In 
this context, perhaps it is useful to reminisce upon the work of Leff et al (28), who described 
the importance of expressed emotion (EE). 
EE is understood as the level of critical comments and hostility toward the affected person 
from a particular carer. Also, the degree of emotional over-involvement of that carer is 
noted (28, 29). Since these topics were first considered, from the late 1950s onwards, high EE 
has been repeatedly and reliably shown to be associated with a higher relapse rate of 
schizophrenia. With the moves towards care in the community of mentally ill people, people 
with long-term mental illnesses living in residential facilities essentially have statutory 
replacements for their biological families. Therefore, the principles of EE are similarly 
applicable. While the degree of EE can be reduced with appropriate staff training, many care 
personnel in residential facilities are amongst the least trained (29). Previous studies in this 
area have found that critical personally directed comments towards people with 
schizophrenia were due to an attribution of dysfunctional behaviours directly to the affected 
person, rather than to their illness. Psycho-education about the nature and natural history of 
schizophrenia is therefore a great help for all those closely involved with it: patients, carers 
and staff members. One of the effects of education is a reduction in EE due to a better 
understanding of the illness process.  
Many of the social aspects of a person’s situation are the pragmatic ones, e.g.  
• Can they care for themselves independently, or do they need help with tasks such as 
eating regularly and maintaining personal hygiene?  
• Do they have enough money to live on? 
• Are they eligible for state benefits? 
• Are they able to work, and if so, how does this affect any benefits? 
• Do they have secure tenancy of their homes? 
One can see that a social worker, or similarly trained professional, is ideally placed to 
answer these concerns. Remembering the holistic package of treatment which should ideally 
be provided for the person with schizophrenia, the significant potential reduction in stress 
makes an important contribution to the maintenance of well-being. 
6. Future developments in the treatment of schizophrenia 
Unfortunately, constraints of space do not permit a full discussion here of potential future 
developments in schizophrenia. With respect to future drug developments, the reader is 
referred to the excellent review by Miyamoto et al (5). The pharmacology section above has 
already mentioned the potential usefulness of nicotinic adjuncts to the treatment of 
schizophrenia. My particular interest is in the use of substances such as nicotine chewing-
gum to provide the short-term enhancement of sensory gating which would normalise the 
dysfunction seen in schizophrenia (10). The sustained activation of nicotinic receptors such 
as that provided by nicotine patches is probably unsuitable, because the involved receptors - 
the α7 nicotinic receptors in the hippocampus- desensitise quickly (13, 30). Galantamine is 
an α7 ligand which allosterically modulates the receptor to increase neurotransmission (30, 
31). The potentiation of nicotinic transmission would therefore be potentially expected to 
transiently improve the sensory gating deficit intrinsic to schizophrenia and thus improve 
symptoms (6, 7, 10). The recognition of the importance of nicotinic neurotransmission in 
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schizophrenia has led to the investigation of drugs such as galantamine as potential 
therapeutic agents for schizophrenia; indeed, symptomatic improvement was seen with the 
addition of galantamine to the therapeutic regime in two very small samples of patients (29, 
30). Enhancement of glutamatergic transmission is another area in which pharmacological 
effort may be directed in the search for new drug treatments for schizophrenia. Noting the 
remarks above about the importance of holistic treatments in mental illness, an obvious 
direction for future treatments in schizophrenia is greater multidisciplinary involvement. 
Recent legislative changes in the UK, with the amendment of the Mental Health Act 1983 in 
2007, pay attention to this. The senior clinician in charge of a service user’s treatment used to 
invariably be the consultant psychiatrist. Under the new Mental Health Act, the person in 
overall charge of the service user’s care is the responsible clinician (RC). The RC can be any of 
the approved clinicians (ACs): 
• a registered medical practitioner 
• a registered mental health nurse (including registered learning disability nurse) 
• a registered occupational therapist 
• a chartered clinical psychologist, and 
• a registered social worker    (32) 
The widening of professions eligible for the senior role of responsible clinician is a reflection 
of greater multidisciplinary involvement in the delivery of care to the service user. Thus, 
more effort is directed towards holistic care, which is important.  
This emphasis provides a useful point at which to close this chapter. One is reminded that 
especially in the mental illnesses, as in all illness, phenomena are interconnected. In 
consequence, change at any point on the pathway of causative/therapeutic events can have 
potential profound effects on all other stages in the pathway. 
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